Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.47 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.45 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | ERN1 | O75460 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29650705 | 1.00 | PRKCI (0.52) | PRKCIDYRK1ADYRK1BDYRK2HDAC3 | |
| SCHEMBL29584645 | 0.88 | DYRK1A (0.46) | PRKCIDYRK1ADYRK1BDYRK2HDAC3 | |
| SCHEMBL753333 | 0.88 | DYRK1A (0.46) | PRKCIDYRK1ADYRK1BDYRK2HDAC3 | |
| SCHEMBL1669250 | 0.84 | CHRM2 (0.41) | PRKCIDYRK1ADYRK1BDYRK2HDAC3 | |
| SCHEMBL29413018 | 0.79 | LMNA (0.48) | DYRK1ADYRK1BDYRK2MAPTRAB9A | |
| SCHEMBL10341 | 0.79 | LMNA (0.48) | DYRK1ADYRK1BDYRK2MAPTRAB9A | |
| SCHEMBL1352302 | 0.79 | ADRA2A (0.36) | PRKCIDYRK1APKMADRA2APNMT | |
| SCHEMBL13182219 | 0.76 | NPC1 (0.44) | MAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL379230 | 0.74 | PRKCI (0.56) | PRKCIDYRK1ADYRK1BDYRK2HDAC3 | |
| SCHEMBL3871171 | 0.74 | MAPT (0.54) | PRKCIDYRK1ADYRK1BDYRK2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665718-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | Apogee Pharmaceuticals, Inc. (CA) | 2025-12-24 | — | — | EP | disclosed |
| US-12378231-B2 | Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof | APOGEE PHARMACEUTICALS, INC. (CA) | 2025-08-05 | — | — | US | disclosed |
| US-20240294514-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | APOGEE PHARMACEUTICALS, INC. (CA) | 2024-09-05 | — | — | US | disclosed |
| WO-2024168426-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | APOGEE PHARMACEUTICALS, INC. (CA) | 2024-08-22 | — | — | WO | disclosed |
| CN-118307453-A | Synthesis method of alkylaryl sulfoxide | 南京工业大学 | 2024-07-09 | — | — | CN | disclosed |
| US-20230339936-A1 | COMPOUND HAVING KINASE INHIBITORY ACTIVITY | CYTOSINLAB THERAPEUTICS CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| US-20230339936-A1 | COMPOUND HAVING KINASE INHIBITORY ACTIVITY | CYTOSINLAB THERAPEUTICS CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| US-20230210854-A1 | MONO- AND COMBINATION THERAPIES | RECURIUM IP HOLDINGS, LLC | 2023-07-06 | — | — | US | disclosed |
| US-20230192687-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2023-06-22 | — | — | US | disclosed |
| US-11560377-B2 | Fused amino pyridine as HSP90 inhibitors | Guris, Inc. (US) | 2023-01-24 | — | — | US | disclosed |
| US-6440995-B1 | NMDA-RECEPTOR SUBTYPE SELECTIVE BLOCKERS | HOFFMAN-LA ROCHE INC. | 2002-08-27 | — | — | US | disclosed |
| WO-2002060877-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-08-08 | — | — | WO | disclosed |
| CN-1290698-A | Quinoline-4-base deviative I | HOFFMANN LA ROCHE (CH) | 2001-04-11 | — | — | CN | disclosed |
| EP-1088818-A1 | Quinolin-4-yl derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-04 | — | — | EP | disclosed |
| EP-0393838-B1 | Dopamine receptor ligands and imaging agents | UNIV PENNSYLVANIA (US) | 1997-06-25 | — | — | EP | disclosed |
| US-5426189-A | Dopamine receptor ligands and imaging agents | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1995-06-20 | — | — | US | disclosed |
| US-5334728-A | Dopamine receptor ligands and imaging agents | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1994-08-02 | — | — | US | disclosed |
| US-5186921-A | 3-methoxy-n(1-ethyl-2-pyrrolidinyl)methyl)naphthyl-2-carboxy amide compounds for imaging human brains; good retention stability | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1993-02-16 | — | — | US | disclosed |
| US-5122361-A | 2-Pyrrolidinylmethylcarboxamido-2,3-dihydrobenzofuran type compounds | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1992-06-16 | — | — | US | disclosed |
| EP-0393838-A1 | Dopamine receptor ligands and imaging agents | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1990-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378231-B2 | Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof | MGLL, PNLIP, LPL | PRKCI 2475/4885DYRK1A 3319/4885DYRK1B 3344/4885 |
| US-20230192687-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | PRKCI 3282/4885DYRK1A 1343/4885DYRK1B 1359/4885 |
| US-20230339936-A1 | COMPOUND HAVING KINASE INHIBITORY ACTIVITY | FLT3, ERBB2, ABL1 | PRKCI 254/4885DYRK1A 428/4885DYRK1B 405/4885 |
| US-20240294514-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | MGLL, PNLIP, LPL | PRKCI 2475/4885DYRK1A 3319/4885DYRK1B 3344/4885 |
| US-20230210854-A1 | MONO- AND COMBINATION THERAPIES | TP53, BRCA1, MCL1 | PRKCI 1536/4885DYRK1A 2472/4885DYRK1B 2246/4885 |
| US-11560377-B2 | Fused amino pyridine as HSP90 inhibitors | HSP90B1, HSP90AB1, HSP90AB2P | PRKCI 3282/4885DYRK1A 1343/4885DYRK1B 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.